This page shows the latest Vyndaqel news and features for those working in and with pharma, biotech and healthcare.
This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.
EU approval will help drug achieve blockbuster status. Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for ... Prior to Vyndaqel, treatment options for patients with ATTR
The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier ... As of the end of 2019 more than 9, 000 ATTR
decision. The two rivals also face competition from Pfizer’s Vyndaqel (tafadamis). It has been available in Europe for a number of years as a polyneuropathy treatment, but recently gained US ... The company also highlighted the fact that around a third
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
Both Vyndamax and Vyndaqel are expected to reduce cardiovascular mortality by 30% and cut cardiovascular related hospitalisation by 32%, strong claims which will help fuel their uptake. ... Vyndaqel has been priced at $225, 000 per year, half the price
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
produced impressive data for its Vyndaqel (tafamidis). ... Vyndaqel has been available in Europe since 2011 for Transthyretin (TTR) amyloid polyneuropathy, but isn’t yet approved in the US.
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...